RxCelerate Wins Best Performing R&D Services Provider Award
Cambridge, UK, 1st April 2025, 1pm BST
We are delighted to share that RxCelerate was named Best Performing R&D Services Provider Company of the Year at last night’s One Nucleus Annual Awards Dinner.
This award is a testament to the expertise, dedication, and innovation of our team, whose commitment to scientific excellence continues to drive real impact in drug discovery and development.
Thank you to One Nucleus and the judging panel for this recognition.
Congratulations to all the finalists and winners!
Notes for Editors
RxCelerate is an outsourced drug discovery and development company based in Cambridge, UK, founded in 2013. It has rapidly grown to become one of the leading providers of drug discovery and development services in the UK. RxCelerate operates a unique model, offering collaborative strategic thinking to clients to help design and execute every aspect of their research and development plans.
RxCelerate offers a comprehensive suite of services covering the entire discovery and development spectrum, including in silico design and discovery, antibody discovery, synthetic and medicinal chemistry, bioanalysis, in vitro services, preclinical services, and project management. Clients can also access RxCelerate’s proprietary platform technologies, including RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics across diverse biological samples. The combination of integrated teams and unique technologies allows RxCelerate to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.
RxCelerate has a team of more than 100 employees based in 25,000 square feet of premium laboratory and office space in the Dorothy Hodgkin Building at the Babraham Research Campus, approximately five miles south of Cambridge, UK, as well as offices in Boston, MA.
For more information, please visit www.rxcelerate.com or contact us at [email protected].